Default: Drug Discovery Today

ISSN: 1359-6446

Journal Home

Journal Guideline

Drug Discovery Today Q1 Unclaimed

Elsevier Ltd. Netherlands
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Drug Discovery Today is a journal indexed in SJR in Drug Discovery and Pharmacology with an H index of 167. It has a price of 2395 €. It has an SJR impact factor of 1,896 and it has a best quartile of Q1. It is published in English.

Drug Discovery Today focuses its scope in these topics and keywords: drug, library, cancer, discovery, clinical, development, drugs, data, crowd, class, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Price

2395 €

Gold OA

-

Green OA

0 €

Non OA

Metrics

Drug Discovery Today

1,896

SJR Impact factor

167

H Index

263

Total Docs (Last Year)

620

Total Docs (3 years)

18902

Total Refs

4384

Total Cites (3 years)

580

Citable Docs (3 years)

7,65

Cites/Doc (2 years)

71,87

Ref/Doc

Aims and Scope


drug, library, cancer, discovery, clinical, development, drugs, data, crowd, class, chitosanbased, gastrointestinal, diabetes, diabetesrenaissance, discoverypcsk, discoverywhat, donors, dopamine, challengeschemogenomics, challenges, analogue, antibodies, approach, approaches, approachescellbased, binding, biology, biomarkers, biomedicinetherapeutic, brain, brainhow, caflux, campaignsan,


Best articles

Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery

View more

Antimalarial drug discovery: development of inhibitors of dihydrofolate reductase active in drug resistance

View more

Antisense Drug Technology: Principles, Strategies, and Applications

View more

Beating superbugs with the Gulliver effect

View more

Bilosomes: the answer to oral vaccine delivery?

View more

Can you stand the heat of today's drug discovery?

View more

Cell signaling: signal transduction and gene transcription

View more

Challengeability of biotechnology patents in the light of Biogen v. Medeva

View more

Chemokines and their receptors

View more

Chiral Europe '95

View more

Chiroscience/BMS MMP inhibitor progress

View more

CombiChem deal

View more
SHOW MORE ARTICLES

Combinatorial approaches to chemistry and biology

View more

Combinatorial chemistry

View more

Combinatorial chemistry

View more

Combinatorial chemistry

View more

Combinatorial chemistry

View more

Combinatorial chemistry

View more

Combining drug-disease and economic modelling to inform drug development decisions

View more

Comparison of some major information resources in pharmaceutical competitor tracking

View more

Corporate intelligence in biotechnology

View more

Could insulin protect against atherosclerosis?

View more

Design and discovery of neuropeptide Y1 receptor antagonists

View more

Diversa and diversity

View more

Comments

No comments ... Be the first to comment!